Immune Therapy Holdings AB or ITH is a Swedish biotechnology R&D holding company headquartered at the Karolinska Institutet and Karolinska University Hospital in Stockholm.
ITH's research is primarily focused on its Tailored Leukapheresis (TLA) treatment for immune mediated inflammatory diseases (IMIDs).